Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
62 hedge funds and large institutions have $115M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 17 closing their positions.
349% more call options, than puts
Call options by funds: $611K | Put options by funds: $136K
1% less capital invested
Capital invested by funds: $116M → $115M (-$1.06M)
6% less funds holding
Funds holding: 66 → 62 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$7.26M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$3.33M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$674K |
| 4 |
SCM
Sio Capital Management
New York
|
+$540K |
| 5 |
DMK
David M. Knott
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$6.48M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.06M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.11M |
| 4 |
Millennium Management
New York
|
-$1.34M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.13M |
FOMX Hedge Fund Activity: Q1 2019 in Review
62 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2019, worth a combined $115M — down 0.91% from $116M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of FOMX and 14 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was DSC Advisors, opening a new position worth an estimated $7.26M. The largest seller was UBS Group, cutting an estimated $6.48M.
- 62 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2019, down from 66 in Q4 2018.
- Funds reported $115M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2019, down 0.91% quarter-over-quarter.
- 14 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2019 and 17 closed out, a net change of -3 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q1 2019 was DSC Advisors, an estimated $7.26M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2019 was UBS Group, an estimated $6.48M sold.
Based on aggregated 13F filings for Q1 2019.